SGX Pharmaceuticals has filed for an IPO designed to raise $80.5 million. The drug developer says it will use much of the money to fund the development of Troxatyl and other research efforts. SGX lost about $13 million in the first half of the year, up from $7.1 million for the same period the year before.
- read this story from Dow Jones for more